Commercial Model Innovation Critical To Win China: McKinsey
This article was originally published in PharmAsia News
Despite a well-tailored product lineup targeting the value market segment being high on top medical device executives’ minds, a more sophisticated commercial model will help win the day in China. In effect, a key shift away from fast sales force expansion towards sophistication and specialization is emerging in the country, notes a new McKinsey study.
You may also be interested in...
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.